Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield – ET HealthWorld

New Delhi: The government has approved Biological E’s Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country. The sources told the media agency that the Union Health Ministry’s approval is based on the recommendations made recently by the Covid-19 Working Group of the National Technical Advisory Group on Immunisation…

Read More

Japan approves Covaxin booster dose for travellers: Bharat Biotech – ET HealthWorld

Hyderabad-based Bharat Biotech on Friday announced that Japan has approved the Covaxin booster dose for travellers. “We are proud to announce, that Japan has approved Covaxin booster dose for travellers. Another global recognition of the effectiveness of our universal Covid vaccine,” Bharat Biotech tweeted. Quarantine Station of Japan’s Ministry of Health, Labour and Welfare issued an advisory for the Quarantine period after entering Japan. In an official statement, the ministry said, “Travelers who are entering or returning to Japan from countries/regions categorized as “RED” in border control measures(28) and who…

Read More

NTAGI panel reviews data for Corbevax as booster for adults who got Covishield, Covaxin shots – ET HealthWorld

New Delhi: The National Technical Advisory Group on Immunisation’s Covid working group has reviewed the data of Biological E’s Corbevax to allow it as booster for those aged 18 and above fully vaccinated with Covishield or Covaxin, official sources said Thursday. No recommendation has yet been made in this matter by the NTAGI panel in its meeting on Wednesday. The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India’s first indigenously developed RBD protein subunit vaccine, Corbevax,…

Read More

Covaxin’s third dose demonstrates persistence of immunity against emerging COVID variants – ET HealthWorld

New Delhi: Hyderabad-based vaccine developer Bharat Biotech on Wednesday announced the administration of third dose of its COVID-19 vaccine BBV152 also known as Covaxin, after six months of two-dose vaccination, dramatically increased neutralizing antibody responses against both homologous and heterologous strains and showed increased memory B cell response. The study was conducted on 184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, 6 months after the primary series of 2 doses. Covaxin induced robust T cell responses and persisted till 6 months,…

Read More

Covid panel to decide today on inclusion of Gennova’s mRNA jab in vaccine drive – ET HealthWorld

Corbevax is the first vaccine approved as a heterologous Covid-19 booster. New Delhi: The crucial meeting of the Covid working group to decide on the inclusion of India’s first mRNA vaccine in the vaccination programme and review Biological E‘s Corbevax as a booster dose for those adults who have received both doses of either Covishield or Covaxin will be held on Wednesday. Both decisions are important in a bigger push to the vaccination drive. “There are about 3% people who are yet to get their Covid-19 shot. The approval of…

Read More

Corbevax & Covaxin approved for U-8 kids yet to be part of govt programme – ET HealthWorld

Nagpur: With school kids being detected Covid positive in the city, there’s a visible fear amongst parents about the health of their wards. Fortunately, Covid vaccination is available for children above 12 years of age and a good number of them have taken at least one dose of the vaccine making them safe from the infection. But there is a section of kids below 12 years which is yet to get vaccinated. Covid has a very mild impact on the Under-8 age group as children recover quickly. So, parents of…

Read More

Covaxin safe and highly immunogenic in children 2-18 years : Lancet journal review – ET HealthWorld

Hyderabad : Bharat Biotech’s BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate is proven to be safe, well-tolerated, and immunogenic in the paediatric population in phase II/III studies, showed a study published in the peer-reviewed journal The Lancet Infectious diseases. The Hyderabad based vaccine maker informed that they have a stockpile of more than 50 million doses of COVAXIN ready to be distributed as required. Bharat Biotech has established COVAXIN manufacturing to reach an annualised capacity of 1 billion doses by the end of 2021. Sharing the details on the…

Read More

NTAGI to review Covaxin, Corbevax data for 6-12 years Thursday, discuss reducing booster dose gap – ET HealthWorld

By Payal Banerjee New Delhi: Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses from the current nine to six months. The National Technical Advisory Group on Immunisation (NTAGI) will hold its meeting amid a fresh spike in COVID-19 cases in the country. Currently, those aged 12 years and above are vaccinated against COVID-19. The agenda for the NTAGI’s Standing Technical Sub-Committee (STSC) meeting includes…

Read More

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study – ET HealthWorld

New Delhi: The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19’s Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found. The protective efficacy of Bharat Biotech’s Covaxin following two and three-dose immunisations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model (animal model to study human-associated diseases), it said. The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge…

Read More

Covid-19: Study finds mixed vaccination boosters work; final decision with Centre – ET HealthWorld

Pune: A study by Christian Medical College, Vellore, on the effectiveness of mixed booster doses has yielded positive results and is currently being evaluated by central agencies, officials from the institute have said. “We presented the results to the National Technical Advisory Group on Immunisation (NTAGI) and our interim analysis to the Drugs Controller General of India. NTAGI listened to our findings, but are yet to make a decision,” said principal investigator of the study, Dr Winsley Rose. The CMC Vellore study found that there can actually be a significant…

Read More